

## 4DMedical appoints Dr Geraldine McGinty to board of directors

25 September 2023

### Highlights

- Internationally recognised leader in health care strategy and imaging economics joins 4DMedical board
- An accomplished academic, researcher, administrator and health care economist, Dr McGinty is Professor of Clinical Radiology and Population Health Sciences, and a certified radiologist practising at, Weill Cornell Medical Center
- Dr McGinty's corporate governance experience spans the American College of Radiology, NextGen Healthcare (NASDAQ:NXGN), Ireland's Industrial Development Authority and the National University of Ireland

**Melbourne, Australia, 25 September 2023:** Respiratory imaging technology company 4DMedical Limited (ASX:4DX, "4DMedical", or the "Company") today announces the appointment of Dr Geraldine McGinty, MD, to the Company's Board of Directors.

Professor of Clinical Radiology and Population Health Sciences, and a certified radiologist practising at Weill Cornell Medical Center, Dr McGinty is an accomplished academic, researcher, administrator and health care economist.

### A leader in healthcare and medical imaging

In 2018, Dr McGinty became the first woman elected as Chair of the American College of Radiology's (ACR) board of Chancellors, making a significant contribution to the ACR through a reorganisation of its Data Science Institute, enabling greater board communication and diversity of opinion. The [ACR](#) is "The Voice of Radiology" in matters of legislation and regulation, and is responsible for guiding radiology reimbursement and coding issues, including relative value units, managed care, alternative payment models, and Medicare regulations.

Prior to this, Dr McGinty headed up the ACR's Commission on Economics. The Commission's work often is used as background material and evidence for ACR congressional and state legislative efforts as well as communications with the [CMS](#) (Centers for Medicare & Medicaid Services), policy makers, and other medical insurers.

Her corporate governance experience includes serving on the Board of NextGen Healthcare (NASDAQ:NXGN), an Atlanta-based provider of software, services and analytical solutions to primary healthcare providers, and as a Non-Executive Director with the Industrial Development Authority (IDA) of the Republic of Ireland, chairing its Audit, Risk and Finance Committee. Dr McGinty is also a member of the Governing Authority of the University of Galway in Ireland.

In her various leadership roles, Dr McGinty has been a powerful and influential voice for women in medical imaging. She has also been instrumental in identifying and mentoring radiologists who push to address health disparities in research, advocacy efforts, artificial intelligence development, and medical student recruitment.



Geraldine McGinty, MD,  
MBA, FACR

#### Melbourne

Level 7 Melbourne Connect  
700 Swanston Street  
Carlton VIC 3053  
Tel: +61 (3) 9545 5940

#### Los Angeles

21255 Burbank Boulevard  
Suite 120  
Woodland Hills CA 91367  
Tel: +1 (818) 403-8490

4DMedical Limited  
ABN: 31 161 684 831  
Email: [info@4DMedical.com](mailto:info@4DMedical.com)  
[www.4DMedical.com](http://www.4DMedical.com)



### Significant and multi-faceted experience across commercial, research, and regulatory environments

Dr McGinty is highly qualified in clinical practice and management, possessing both a medical degree from the National University of Ireland and a master's degree in business administration from Columbia University.

Dr McGinty's academic stature is reflected in her appointment as Professor of Clinical Radiology at Weill Cornell Medicine where she is concurrently Senior Associate Dean of Clinical Affairs. In 2017, Dr McGinty was appointed as founding Academic Director for the Executive MBA and Masters in Healthcare Leadership program delivered jointly by Weill Cornell and the Cornell University SC Johnson School of Business, a role she performed until 2019.

### Specific expertise in reimbursement

Dr McGinty's published work has focused on payment models for imaging, most recently a bundled payment for breast cancer screening. Recently she has focused on the impact of Artificial Intelligence on Medical Imaging and has spoken at the Turing Institute and to the WHO Focus Group on AI in Healthcare on this topic.

As a member of the American Medical Association's Relative Value Unit Update Committee from 2012-2016, Dr McGinty was instrumental in recommending reimbursement policy to Medicare, thereby impacting the economics of the entire U.S. healthcare delivery system.

In addition, from 2015 to 2021, Dr McGinty was Chief Strategy and Contracting Officer within Weill Cornell responsible for fee-for-service and value-based payment arrangements.

### Dr Geraldine McGinty commented:

*Over my years of experience in healthcare I have seen many companies fail because they were unable to engage with the complex systems of payment, and I am excited by the opportunity to help 4DMedical navigate through these systems and thereby drive their innovative technology to create positive change in healthcare.*

### 4DMedical MD/CEO and Founder Andreas Fouras said:

*The appointment of Geraldine McGinty to 4DMedical's Board of Directors brings wide-ranging expertise in health care strategy and medical imaging economics to the team. Dr McGinty's commitment to service of the community through quality patient care aligns with 4DMedical's culture, and I am absolutely thrilled to have a leader of Geraldine's stature and integrity join our mission.*

—ENDS—

Authorised by the 4DMedical Board of Directors.

### Contacts

#### Corporate

Chief Financial Officer  
Simon Glover  
[sglover@4dmedical.com](mailto:sglover@4dmedical.com)

#### Administration

Company Secretary  
Naomi Lawrie  
[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

#### Media Enquiries

The Capital Network (TCN)  
Julia Maguire  
[julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)



## About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit [www.4dmedical.com](http://www.4dmedical.com).